Docetaxel, Cisplatin, 5-Fluorouracil (TPF)-Based Induction Chemotherapy for Head and Neck Cancer and the Case for Sequential, Combined-Modality Treatment
Robert I. Haddad(Georgetown University), Marshall R. Posner(Icahn School of Medicine at Mount Sinai), Lori J. Wirth(Massachusetts General Hospital), Laura A. Goguen(Brigham and Women's Hospital), Paul M. Busse(Massachusetts General Hospital), Charles M. Norris, Roy B. Tishler(Dana-Farber Cancer Institute), Christopher A. Sullivan(Brigham and Women's Hospital), Anand Mahadevan(Geisinger Medical Center), Rosemary Costello(Dana-Farber Cancer Institute), Mary Ann Case(Dana-Farber Cancer Institute)
Cited by 58
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Recent Advances in Head and Neck Cancer
|New England Journal of Medicine|2008|926